VDJ engages in the R&D of monoclonal antibody drugs.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 3, 2018 | Series C | ¥30M | 1 | Beijing Youhe Dingxin Equity Investment Management | — | Detail |
Dec 13, 2017 | Series B | ¥20M | 1 | Beijing Hankang Chuangye Touzi | — | Detail |
Sep 30, 2016 | Series A | ¥3M | 1 | — | — | Detail |
Jun 4, 2014 | Angel | ¥3M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Beijing Youhe Dingxin Equity Investment Management | Yes | Series C |
Beijing Hankang Chuangye Touzi | Yes | Series B |
Beijing Yinglida Biological Technology | — | Series A |
KMT Technology | — | Angel |